News of combined therapy of moderate and severe asthma in children
https://doi.org/10.18093/0869-0189-2007-0-4-12-16
Abstract
Efficiency of different regimens of long-term maintenance combined therapy with budesonide / formoterol (fixed doses in the 1st group and flexible doses in the 2nd group) was evaluated in 60 moderate or severe bronchial asthma children during 12 weeks. The 2nd group patients demonstrated more prominent improvement in all asthma symptoms. Frequency of asthma attacks decreased significantly in both the groups within the followup period (from 3.5 ± 0.18 to 1.27 ± 0.14 (p < 0.05) in the 1st group and from 2.5 ± 0.2 to 0.25 ± 0.09 (p < 0.01) in the 2nd group). Three months after starting the treatment, need in short-acting β2 -agonists greatly decreased in the 2nd group (1.37 ± 0.19 vs 0.5 ± 0.09; p < 0.044). Lung function parameters (PEF, FEV1) came to normal in both the groups. The total number of doses of budesonide / formoterol spent for 12 weeks differed between the groups: 168 ± 4.2 doses per 1 children, or 262.8 ± 8.3 μg of budesonide per 1 day per 1 children in the 1st group and 114 ± 3.9 doses per 1 children, or 185.6 ± 5.6 μg of budesonide per 1 day per 1 children in the 2nd group (p < 0.05). Therefore, the maintenance therapy with flexible-dose budesonide / formoterol was more effective that fixed-dose regimen in terms of reduction in exacerbation rate, need in short-acting β2 -agonists and the total amount of inhaled corticosteroids used.
About the Authors
N. A. Gheppae
Московская медицинская академия им. И.М.Сеченова
Russian Federation
Russian Federation
A. R. Denisova
Московская медицинская академия им. И.М.Сеченова
Russian Federation
Russian Federation
N. I. Sokolova
Московская медицинская академия им. И.М.Сеченова
Russian Federation
Russian Federation
References
1. Дрожжев М.Е., Лев Н.С., Костюченко М.В. и др. Современные показатели распространенности бронхиальной астмы среди детей. Пульмонология 2002; 1: 42–46.
2. GINA, Global strategy for asthma management and prevention. www.ginasthma.org.
3. Национальная программа "Бронхиальная астма у детей. Стратегия лечения и профилактика". Пересмотр от 2006 года. М.; 2006.
4. McFadden E.R., Casale T. B., Edwards T.B. et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46–52.
5. Kallen B., Rydhstroem H., Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstetr. and Gynecol. 1999; 93: 392–395.
6. Agertoft L., Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064–1069.
7. Kips J. C., O,Connor B. J., Inman M. D. et al. A long-termed study of the antiinflammatory effect of low-dosed budes-onide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996–1001.
8. Severova E., Anderson A. Oxis (formoterol given by Turbuhaler) shoved as rapid an onset of action as salbutamol given by a pMDI. Respir. Med. 2000; 94: 607–611.
9. Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Руководство для врачей России (формулярная система). Пульмонология 2001; 1: 65–72.
10. British Thoracic Soсiety and SCOTTISH Intercollegiate Guidelines Network Guidelines on Asthma. Thorax 2003; 58: 1–94.
11. Aalbers R., Basker V., Kava T.T. et al. Adjuistable maintenance dosing with budesonide/formoterol compared with fixed dose salmeterol / fluticasone in moderate to severe asthma. Curr. Med. Res. Opin. 2004; 20: 225–240.
Review
For citations:
Gheppae N.A., Denisova A.R., Sokolova N.I. News of combined therapy of moderate and severe asthma in children. PULMONOLOGIYA. 2007;(4):12-16. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-4-12-16
Views:
291
Email this article 